DUNTON ALAN W 4

What Happened

• Alan W. Dunton, a director of CorMedix, was granted 30,453 restricted stock units (RSUs) on January 26, 2026. The grant price is recorded as $0.00 (no cash was paid at grant); the reported transaction value is $0 at issuance. Each RSU represents the right to one share of CorMedix common stock and will vest in full on January 26, 2027, subject to continued service on the vesting date.

Key Details

• Transaction date: 2026-01-26; Form filed: 2026-01-27 (timely filing).
• Grant amount: 30,453 RSUs; grant price: $0.00; reported dollar amount: $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: RSUs convert 1-for-1 to shares and vest in full on 2027-01-26 if Dunton remains in service.
• Exhibit included: 24.1 — Power of Attorney.

Context

• This was an equity award for compensation (not an open-market purchase or sale). RSUs typically result in issuance of shares at vesting (which may dilute existing shares) and are usually taxed when they vest or shares are delivered. The filing does not indicate any immediate sale or exercise of options.